Company

Our current pre-clinical development programs focus on the development of treatments for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer.

DFE Pharma develops, produces and supplies excipients for use in oral solid dose and dry powder inhalation,

TropIQ Health Sciences offers laboratory screening services for the discovery and development of drugs against malaria.

Protinhi Therapeutics is an early stage biotech company, developing novel drugs against diseases with a high unmet medical need using proprietary technology and compounds that target diseases via Protease Inhibition. The focus of Protinhi is on upcoming viral threats and particularly on Dengue and Zika.

Okklo Life Sciences is a privately held biopharmaceutical company developing novel therapeutic solutions using cyclodextrin-based technologies, with a focus on neglected and orphan diseases.